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Abstract
Background: In Australia, breast cancer is the most common cancer affecting Australian women. Inequalities in
clinical and psychosocial outcomes have existed for some time, affecting particularly women from rural areas and
from areas of disadvantage. We have a limited understanding of how individual and area-level factors are related
to each other, and their associations with survival and other clinical and psychosocial outcomes.
Methods/Design: This study will examine associations between breast cancer recurrence, survival and psychosocial
outcomes (e.g. distress, unmet supportive care needs, quality of life). The study will use an innovative multilevel
approach using area-level factors simultaneously with detailed individual-level factors to assess the relative
importance of remoteness, socioeconomic and demographic factors, diagnostic and treatment pathways and
processes, and supportive care utilization to clinical and psychosocial outcomes. The study will use telephone and
self-administered questionnaires to collect individual-level data from approximately 3, 300 women ascertained from
the Queensland Cancer Registry diagnosed with invasive breast cancer residing in 478 Statistical Local Areas
Queensland in 2011 and 2012. Area-level data will be sourced from the Australian Bureau of Statistics census data.
Geo-coding and spatial technology will be used to calculate road travel distances from patients’ residence to
diagnostic and treatment centres. Data analysis will include a combination of standard empirical procedures and
multilevel modelling.
Discussion: The study will address the critical question of: what are the individual- or area-level factors associated
with inequalities in outcomes from breast cancer? The findings will provide health care providers and policy
makers with targeted information to improve the management of women with breast cancer, and inform the
development of strategies to improve psychosocial care for women with breast cancer.
Background
Breast cancer is the most common cancer in women
worldwide. It is estimated that 1.38 million women will
be diagnosed with breast cancer in 2008 [1]. In Australia
in 2007, 12, 567 women were diagnosed with breast can-
cer accounting for 27% of cancer diagnoses. Breast cancer
is the second leading cause of cancer mortality (15% of all
cancer deaths) overall, [2] and among women, it is the
leading cause of premature mortality due to cancer [3].
Women diagnosed with breast cancer carry a significant
psychological burden. Prevalence studies suggest that
33% of women with breast cancer will experience clini-
cally significant psychological distress (e.g. anxiety and/or
depression) that for many will persist over time, [4] and
approximately one-third report moderate to high unmet
supportive care needs after their diagnosis [5].
Inequalities in survival, recurrence, treatment and
psychosocial outcomes
There is a consistent rural gradient in breast cancer inci-
dence, being higher in major cities, and lower in more
rural areas [6-8]. In contrast survival tends to be lower for
women living in more rural areas. In Queensland Australia,
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women from inner regional areas, 24% lower in outer
regional areas and 41% lower in remote areas compared to
the major city area with similar patterns observed in other
Australian states [9,10]. Patterns of treatment also vary
geographically with women living in rural and remote
areas up to 70% more likely to receive a mastectomy than
breast conserving surgery, independent of disease stage
[11]. Possible factors contributing to this differential
include the need for women in rural areas to travel greater
distances to radiotherapy services and lack of local access
to tertiary hospitals [11,12]. Additionally, there is some evi-
dence to suggest that rural women may perceive, or actu-
ally have, less control over treatment decisions, and this
may be due to limited access to information about options
for breast cancer treatment [13]. Emerging evidence sug-
gests that rural cancer patients experience greater psycho-
logical morbidity than do their urban counterparts [14]
and rural women report more unmet needs for help in
dealing with fears about cancer recurrence [5].
Possible reasons for observed inequalities in outcomes
Stage
Differences in stage are a possible reason for the observed
differences in breast cancer survival. Cancer stage is the
most strongly predictive of all clinical prognostic factors:
5-year relative survival rates vary from about 98% for
women with tumours ≤ 10 mm to 73% for women with
tumours 30 mm+ and 49% for those women with tumours
of unknown size [10]. However a recent ecological study
in Queensland, Australia found significant differences in
5-year survival by rurality that remained after adjusting for
spread of disease, [10] suggesting these differences in sur-
vival are not explained by geographical variation in the
proportions of women diagnosed with early versus late
stage breast cancer.
Age
There is biological evidence to suggest that breast cancer
among younger women is a distinct disease [15]. Tumours
tend to be larger, less well differentiated, more likely to be
lymph-node positive and more likely to metastasise com-
pared to tumours found in older women. As a result, prog-
nosis is significantly worse among younger breast cancer
patients, and they are more likely to experience recurrence
[15-17]. Compared to older women, women less than 50
years of age are more likely to experience high levels of
psychological distress after breast cancer and greater
ongoing psychosocial support needs [18]. Younger women
also experience more problems with sexual well-being
after breast cancer, [19] including concerns about prema-
ture menopause; fertility and sexual functioning; [20]
greater decrements in social well-being; greater financial
difficulties; [21] and they consistently report that existing
supportive care services do not match their needs [22].
Risk factors
Apart from age and family history, risk factors for breast
cancer include reproductive or hormonal factors, [23] as
well as health-related factors such as obesity, smoking,
alcohol intake and reduced levels of physical activity
[24-26]. Those living in rural areas and areas of disadvan-
tage are more likely to have poorer health-related beha-
viours [27]. Further, a high body mass index and current
smoking have been found to be associated with reduced
survival [28].
Access to screening and health services
Screening for breast cancer in asymptomatic women is
estimated to reduce mortality by 20% to 35% [29,30]. In
Australia, free biennial population-based screening is
available for women in the target age group of 50 to 69
years, although women aged 40-49 years and over 70
years are also able to take part. Approximately 55% of
Australian women in the target age group participated
in the breast screen program in 2007-2008 [31]. While
higher participation rates have been observed in regional
and remote areas compared to major cities, low partici-
pation rates have been observed in the most socially dis-
advantaged areas and among Indigenous women [32].
Location of and access to, health services have been
recognised as important contributors to morbidity and
mortality in Australia and elsewhere. While the increasing
centralisation of health care services [33] is supported by
evidence that the best outcomes are obtained when
patients are treated by practitioners and institutions with
high caseloads, [34] this centralisation has implications for
rural cancer patients’ access to diagnostic and treatment
services. Typically rural patients need to travel longer dis-
tances to access those services, and this may be a disincen-
tive to undertake or complete treatment regimens. This is
particularly relevant when the treatment involves a pro-
longed absence from home resulting in disruptions to
family life and financial hardship [35].
Indigenous status
While the incidence of breast cancer in Indigenous
Australian women is lower than that of non-Indigenous
women, it is still the most common cancer in this group
[6,36]. Once diagnosed with breast cancer, Indigenous
women have significantly poorer survival than their non-
Indigenous counterparts [10]. One factor contributing to
this disparity is that Indigenous Australians are signifi-
cantly more likely to live in rural and remote areas than
are non-Indigenous Australians [37].
Socioeconomic status
In Australia the incidence of breast cancer is about 15%
higher for women living in areas of high SES compared
to those living in the most disadvantaged areas [6]. Simi-
lar patterns have been observed in the USA and Europe
with incidence rates about 10-20% higher for women liv-
ing in the least deprived areas [38-40]. However, women
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rates of recurrence. While some of the survival differen-
tial is explained by stage of disease, significant differences
in survival remain after adjustment for tumour size,
stage, age at diagnosis and treatment [41,42]. In a recent
study examining both area- and individual-level SES,
after adjustment, there remained a persistent association
for higher mortality for women who lived in commu-
nities where a high proportion of residents had limited
educational attainment [43].
SES also influences choice of treatment with women
from lower SES groups significantly less likely to
undergo breast conserving surgery independent of dis-
ease stage and less likely to undergo or to complete
adjuvant therapy despite this being the recommended
treatment [44,45]. Lower SES has also been shown con-
sistently to predict poorer psychological outcomes after
cancer [46].
Area-level versus individual- level factors
Most studies examining area variation in cancer outcomes
have used an aggregate ecologic design [47,48]. This has
well-documented conceptual and statistical difficulties in
interpretation [49]. Survival studies using aggregated eco-
logic data are unable to quantify whether the variations in
survival are likely due to the clustering of individuals or
the environmental characteristics of the areas in which the
individuals live. Ecologic studies leave open the possibility
that variation between clinical and psychosocial outcomes
is explained by varying population compositions, and
unless these are taken into account, area- and individual-
level sources of variation are confounded.
By obtaining detailed information about individual
breast cancer patients through clinical records, telephone
interviews and self-administered questionnaires, supple-
mented by area-specific information, this study will incor-
porate a multilevel approach to investigating inequalities
in outcomes, and thus overcome many of the methodolo-
gical and interpretive problems of ecologic studies.
Study Aims
1. To systematically describe modes of presentation,
time to diagnosis, diagnostic and treatment path-
ways, utilisation of psychosocial care services, unmet
supportive care needs, perceptions of control over
treatment decisions, rates of recurrence and survival
for women newly diagnosed with breast cancer.
2. To examine differences in these factors accord-
ing to individual characteristics (including age (<
50 years, 50-69 years and 70+ years), spread of dis-
ease, co-morbidity and individual-level socioeco-
nomic status) and area-level characteristics
including geographical remoteness, area socioeco-
nomic disadvantage.
3. To model the independent contribution that area-
level and individual-level factors make to the varia-
tion in recurrence and survival from breast cancer.
Methods/Design
Funding and support
This project was awarded funding by Cancer Australia (ID:
1006339). Cancer Council Queensland provided additional
funding for the maintenance of the GIS software and for
the long-term follow-up of breast cancer cases.
Ethical clearance
Approval for the study was obtained from the Human
Research Ethics Committee of Griffith University,
Australia (PSY/C4/09/HREC). Additional clearance to
access confidential health information was obtained from
the Research Ethics and Governance Unit, Queensland
Health.
Study Design
This study involves the collection and modelling of indivi-
dual- and area-level data. Individual-level data will be
obtained through a longitudinal study of women newly
diagnosed with breast cancer. Quantitative and qualitative
data will be collected by Computer Assisted Telephone
Interview (CATI) and self-administered questionnaires
(SAQ) at two time points: 4 to 6 months post diagnosis
(Time 1) and 18 months post-diagnosis (Time 2). Clinical
and treatment information will be obtained from medical
records at 12 months post diagnosis. Information on
mammographic screening, surgical and other therapeutic
procedures will be obtained from BreastScreen Australia,
Medicare Australia and through the Queensland Hospital
Admitted Patient Data Collection (QHAPD). Information
on recurrence and survival will be obtained using Queens-
land and interstate Cancer Registries and the National
Death Index. Area-level data will be obtained from the
Australian Bureau of Statistics.
Setting
The study will be conducted in Queensland Australia.
Queensland is the third largest Australian state by popula-
tion with an estimated resident population of 4.5 million
(2010). Queensland is the most decentralised state in
Australia with approximately 40% of its population living
outside of its capital city and surrounding area [50].
Study participants
Eligible participants will be all women aged 20 to 79
years resident in Queensland, Australia with a histologi-
cally confirmed diagnosis of invasive breast cancer
(ICD0-3 C50) between January 1 2011 and December 31
2012 and notified to the Queensland Cancer Registry
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virtually universal coverage of individuals diagnosed
with cancer in Queensland. Notification of cancer is a
statutory requirement for all pathology services, private
and public hospitals and nursing homes in Queensland.
Based on Queensland incidence rates, [9,51] and allow-
ing for increasing trends in counts, [9] it is anticipated
that approximately 5, 185 women will be eligible. Patients’
name and the names of their treating doctors will be
obtained from the QCR using a rapid ascertainment pro-
cedure that will minimise the time from diagnosis to
ascertainment to approximately four months. Following
doctor’s consent, all patients will be forwarded a study
information sheet, consent form and reply-paid envelope
along with a letter from their doctor informing them of
the study. Participants will also be asked to provide con-
sent for researchers to access their records within the
QCR and to allow matching of their name to other data
sources. Non-responding patients will be followed-up by
repeat mailing and telephone.
Data collection
Individual-level data
I n f o r m a t i o no b t a i n e df r o mt e l e p h o n ea n ds e l f -
administered questionnaires Participants will receive a
structured telephone interview and a self-administered
questionnaire (SAQ) at 4 to 6 months (Time 1) and at 18
months (Time 2) post diagnosis. Information collected will
include socio-demographics, self-reported diagnostic and
treatment information, medical information, attitudes to
help seeking, utilisation and availability of psychosocial
and supportive care, psychological distress and quality of
life.
Socio-demographics will include education, marital sta-
tus, occupation, private health insurance, gross house-
hold income (pre and post diagnosis), number of
dependent children at home and Indigenous status.
Medical history will include family history of breast
cancer, birth weight, age at menarche, menopausal status,
parity, history of breastfeeding, use of oral contraceptives
and hormone replacement therapy (HRT), complementary
therapies, current weight, pre-diagnosis weight, pre-
existing medical conditions, smoking, and alcohol con-
sumption and levels of physical activity.
Pathways to diagnosis will include history of mammo-
graphy (through public and private facilities), symptoms
and date of first recognition of abnormality (for symptom
detected), date of mammography (for screen detected),
date and outcomes of first appointment with doctor, date
and outcomes of any subsequent appointments up to the
date of diagnosis, methods of transport and time taken to
attend diagnostic tests, satisfaction with the process of
diagnosis (including perceived delays, reasons for delays).
Treatment pathways will include treatment types and
corresponding dates, location of treatment facility, time
taken and method of transport to attend treatments,
satisfaction with medical care and health system, reasons
for treatment choices, perceived degree of control over
choices and barriers from the patient’s perspective.
Psychosocial outcomes will be assessed using a number
of previously validated instruments including the Attitudes
to Seeking Help after Cancer (ASHCa) a 20 item scale that
assesses positive and negative attitudes to seeking emo-
tional or psychological support after cancer and beha-
vioural intention to seek support [31,52]. The Supportive
Care Needs Survey Short Form 34 (SCNS-SF34) a 34-item
survey assessing cancer patients’ need for help over the
last month across 5 domains: psychological, health systems
and information, patient care and support, physical and
daily living, and sexuality needs. It has well demonstrated
reliability and validity in cancer populations [53]. Percep-
tions of control over treatment choices will be assessed
using questions developed by Street and Voigt [54] and
Jansen et al. [55]The Brief Symptom Inventory - 18 (BSI-
18) will be used to assess psychological distress through
three subscales of anxiety, depression, and somatisation.
This scale has been well validated in oncology settings and
has also been validated with non-clinical populations in
the community [56]. Finally, Quality of Life will be
assessed using the FACT-B, which has good reliability and
validity and has been used in rural patients and among
breast cancer survivors in Australia [57,58]. The FACT-B
assesses physical, social, emotional and functional well-
being.
Queensland Cancer Registry Data Information obtained
from the QCR will include date of birth, address at diag-
nosis, treating physician’s name and contact details, date
of diagnosis, tumour site, morphology, histological grade,
stage, degree of lymph node involvement, oestrogen and
progesterone status. Indigenous status will also be col-
lected from QCR records and will be cross-checked
against information provided by the participant during
the telephone-based interview.
Medical record data At 12 months after diagnosis, infor-
mation on diagnosis and treatment including diagnostic
tests, presenting symptoms, type and date of surgical pro-
cedures, post-operative complications and other therapy
(radiation, cytotoxic or hormonal therapy), including start
and completion dates will be extracted from clinician and
hospital records. Information on indicators of illness sta-
tus and disease progression including stage, tumour site,
maximum tumour diameter, lymph node status, presence
of distant metastases and other prognostic indicators will
also be obtained. Mammographic history (including
dates, location and results) will be obtained from the rele-
vant public or private breast screening services.
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system (Medicare) provides access to free treatment at a
public hospital and free or subsidised treatment by med-
ical practitioners and specialists. Following additional
consent from study participants, data relating to specia-
list attendances, surgical and therapeutic procedures,
and pharmaceutical usage will be extracted from the
Medicare database from 1
st J a n u a r y2 0 1 1f o rt h en e x t
five years.
Long-term follow-up of participants Using the QCR,
other Australian state and territory cancer registries,
and Australia’s National Death Index, participants will
be followed for a total of five years from their date of
diagnosis for breast cancer recurrence, diagnosis of
other primary cancers, and death (classified as breast
cancer, other cancer or non-cancer death).
Area-level information
Statistical local areas (SLA) will be the primary focus for
area-level analysis. SLAs comprise a group of census col-
lection districts (CDs), the smallest geographical area used
by the Australian Bureau of Statistics. In 2006 there were
478 SLAs in Queensland with a median population of 5,
810 individuals. SLAs are often based on the incorporated
bodies of local governments who are responsible for ser-
vice provision and infrastructure at the local and regional
level.
Remoteness Remoteness of residence when diagnosed
with breast cancer will be categorised using the ARIA+
classification, which is a measure of accessibility and
remoteness based on geographical location [59]. This
classification includes Major City, Inner Regional, Outer
Regional, Remote and Very Remote.
Access to cancer treatment centres and medical care
As the ARIA+ classification does not account for access to
specialised treatment facilities, specific categories based on
distance to and from each facility will be developed. Dis-
tance to treatment facilities will be calculated from the
participant’s place of residence. Address details for breast
cancer patients, treatment facilities and diagnostic services
will be geocoded using the Manifold
® GIS System, a com-
mercial package designed to clean and convert address
information into latitude and longitude coordinates. Road
travel distances and times between these locations will be
calculated using Manifold
® GIS system, combined with
street network analysis and custom GIS applications.
Measures of socioeconomic status Area-level socioeco-
n o m i cd i s a d v a n t a g ew i l lb em e a s u r e du s i n gt h eI n d e xo f
Relative Socioeconomic Disadvantage (IRSD) calculated by
the Australian Bureau of Statistics (ABS) [60]. The IRSD
provides a general measure of disadvantage, and considers
factors such as low income, low educational attainment,
high unemployment, and jobs in unskilled occupations.
Area-level information about education levels, household
income, types of occupation, median mortgage and rental
payments and other socioeconomic indicators (corre-
sponding to the relevant information collected at the indi-
vidual level) by age group and sex for each SLA will be
obtained from the census data files released by the ABS
for 2006 and 2011.
Life expectancy A v e r a g el i f ee x p e c t a n c yw i l lb ec a l c u -
lated from the unit record mortality file for Queensland
from the ABS that contains year-specific details of all-
cause mortality by SLA.
Primary outcome measures
Diagnostic pathways will be assessed through the collec-
tion of information describing events and the time period
from participants’ first noticing symptoms or first abnorm-
ality on routine screening exam to first presentation to the
medical practitioner. The diagnostic interval will be calcu-
lated as the time between initial presentation and the defi-
nitive diagnosis.
Treatment pathways will include a description of
events and the time taken from definitive diagnosis to
the commencement of primary treatment and then the
time taken from primary treatment to subsequent treat-
ment(s).
Time to recurrence will be calculated from the date of
initial diagnosis to the date of first recurrence. Survival
will be calculated from the date of initial diagnosis to the
end of the follow-up period (five years) or death.
Sample size and power calculations
Based on the number of women diagnosed with breast
cancer in Queensland from 2005-2007, [51] and recent
trends in incidence counts, approximately 5, 185 women
aged 20 to 79 years at diagnosis will be eligible for the
study. Survival with breast cancer in Queensland is 95.5%
one year after diagnosis and 91.3% at two years. Assuming
that, doctor’s permission is obtained to contact 85% of
patients, and 75% of these patients agree to participate
with an additional 5% loss-to-follow up in the second year
of the study, the actual sample sizes would be 3, 305 at
time 1 and 2, 985 at time 2.
The 5-year cause-specific survival for women in Queens-
land diagnosed with invasive breast cancer when living
within 2 hours road travelling time from a radiation facility
is 0.897, compared to 0.851 for women living further away
(unpublished data, QCR). Applying these estimates to the
anticipated sample size (n = 2982; n = 2289 < 2 hrs; n =
692 ≥2 hrs) and using a two-sided log rank test, we would
expect 80% power at a 5% significance level to detect an
absolute survival difference of 4%, or an approximate
hazard ratio of 1.4. This equates to 356 breast cancer
deaths expected among the study cohort within 5 years.
Power calculations for the variation between and within
area units (using Optimum Design software) are based
solely on the approximate number of clusters (i.e. SLA)
and records per cluster. We expect the sample at time 2 to
cover 418 area units (SLAs), with between 1 and 69 (mean
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clusters with an average of 7 records per cluster and a
baseline proportion of 50% gives 85% power at 0.05% sig-
nificance to detect a difference in proportions between
two groups of 6% at time 2.
Statistical analysis
Statistical analyses will be conducted using a combina-
tion of standard empirical procedures and multilevel
modelling (MLwiN 2.23). Time to diagnosis and treat-
ment will be analysed using standard methods such as
geometric mean (to account for anticipated skewed dis-
tribution of time to diagnosis and treatment) or the
median.
Multilevel modelling (Cox proportional hazards)
includes individual-level factors (level 1) and the indica-
tors of geographic remoteness and area socioeconomic
disadvantage (level 2). This approach extends traditional
(single-level) proportional hazards modelling by incor-
porating a random intercept that reflects the average
survival outcome (time or probability) for each area.
Corresponding models will be used for count (based on
the Poisson or Negative binomial distribution) and cate-
gorical (based on the binomial distribution) data.
The multi-level modelling strategy consists of three
stages. Firstly, building on the null (intercept only) model,
this includes individual-level factors (such as patient char-
acteristics, disease stage, co-morbidity, and access to
health care and treatment services) as fixed effects. This
will tell us how much of the area-variation in the breast
cancer outcomes is due to these compositional factors;
and also assess the contribution of each individual-level
factor, including age to these outcomes. The second
model extends Model 1 by including the area-level vari-
ables such as geographic remoteness and area socioeco-
nomic disadvantage as fixed effects. This will quantify how
much of the area-variation in the diagnostic pathway,
treatment choices, unmet needs, and psychological adjust-
ment and recurrence and survival is due to the area-level
factors, independently of the individual-level factors. In
the third model we specify cross-level interactions between
the individual-level factors and geographic remoteness and
area disadvantage. This analysis will tell us if the relation-
ship between breast cancer outcomes and each of the indi-
vidual-level factors differs as a function of geographic
remoteness or area disadvantage.
Discussion
Breast cancer is the most common cancer in women in
Australia. As the population increases and ages, the num-
ber of women diagnosed with breast cancer will increase,
increasing the already significant burden on health care
services. Inequalities in clinical and psychosocial out-
comes, including poorer survival continue for women
from rural and regional areas and for women from areas
of disadvantage. The study will use an innovative approach
to investigate reasons for these inequalities. Applying
multi-level modelling techniques to examine area-level
factors simultaneously with detailed individual-level fac-
tors will enable us to build a more complete picture of
what are the important contributors to these known
inequalities and how these factors relate to each other.
This study will enable us to determine whether geo-
graphical areas themselves have an impact on outcomes
from breast cancer independently of the characteristics
of the women who live in these areas. It will provide
health care providers and policy makers with targeted
information to improve the future management of
women with breast cancer, and inform the development
of strategies to improve psychosocial care for women
with breast cancer.
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